Xenetic Biosciences Inc reports results for the quarter ended in December - Earnings Summary

Xenetic Biosciences

21/03/2024 21:51

* Xenetic Biosciences Inc  XBIO.OQ  reported a quarterly
adjusted
loss of 77 cents​​ per share for the quarter ended in December,
higher than the same quarter last year, when the company
reported EPS of $-1.00.  The lone analyst forecast for the
quarter was for a loss of 87 cents per share. 
    * Revenue rose 38.3% to $672.00 thousand from a year ago;
analysts
expected $680.00 thousand. 
    * Xenetic Biosciences Inc's reported EPS for the quarter was
a
loss of 77 cents​.
    * The company reported a quarterly loss of $1.17 million.
    * Xenetic Biosciences Inc shares had risen by 21.7% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "hold"

This summary was machine generated from LSEG data March 21 at
09:50 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.87          -0.77          Beat
 Sep. 30 2023      -1.12          -0.69          Beat
 Jun. 30 2023      -1.13          -0.69          Beat
 Mar. 31 2023      -1.10          -0.60          Beat